PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Bioengineering and California Institute for Quantitative Biosciences (QB3), University of California at Berkeley, Berkeley, California, USA.\', \'Simula Research Laboratory, Oslo, Norway.\', \'Department of Chemistry, University of California, Berkeley, California, USA.\', \'Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.\', \'Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California, USA.\', \'Department of Pharmacology, School of Medicine, University of California at Davis, Davis, California, USA.\', \'Department of Materials Science and Engineering, University of California at Berkeley, Berkeley, California, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1111/cts.13038
?:hasPublicationType
?:journal
  • Clinical and translational science
is ?:pmid of
?:pmid
?:pmid
  • 33786981
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.669
?:rankingScore_hIndex
  • 31
is ?:relation_isRelatedTo_publication of
?:title
  • In vitro safety \'clinical trial\' of the cardiac liability of drug polytherapy.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all